Your browser doesn't support javascript.
loading
Secondary Breast Cancer Sociodemographic Characteristics and Survival by Age Group.
Sauder, Candice A M; Li, Qian; Bold, Richard J; Ruddy, Kathryn J; Keegan, Theresa H M.
Afiliación
  • Sauder CAM; Division of Surgical Oncology, Department of Surgery, Davis Medical Center, University of California, Sacramento, CA, USA. camsauder@ucdavis.edu.
  • Li Q; Comprehensive Cancer Center, Davis Medical Center, University of California, Sacramento, CA, USA. camsauder@ucdavis.edu.
  • Bold RJ; Division of Hematology and Oncology, Center for Oncology Hematology Outcomes Research and Training (COHORT), University of California Davis School of Medicine, Sacramento, CA, USA.
  • Ruddy KJ; Division of Surgical Oncology, Department of Surgery, Davis Medical Center, University of California, Sacramento, CA, USA.
  • Keegan THM; Comprehensive Cancer Center, Davis Medical Center, University of California, Sacramento, CA, USA.
Ann Surg Oncol ; 28(13): 8118-8127, 2021 Dec.
Article en En | MEDLINE | ID: mdl-34185208
BACKGROUND: Secondary cancers account for 16% of all new cancer diagnoses, with breast cancer (BC) the most common secondary cancer. We have shown that secondary BC has unique characteristics and decreased survival compared with primary BC in adolescent and young adults (AYA; 15-39 years old). However, older BC populations are less well studied. METHODS: Females (age ≥ 15 years) diagnosed with primary BC during 1991-2015 (n = 377,167) and enrolled in the California Cancer Registry were compared with those with secondary BC (n = 37,625) by age (15-39, 40-64, ≥ 65 years). We examined BC-specific survival (BCSS) accounting for other causes of death as a competing risk using multivariable Cox proportional hazards regression. RESULTS: Most secondary BC patients were of older age (15-39, n = 777; 40-64, n = 15,848; ≥ 65, n = 21,000). Compared with primary BC treatment, secondary BCs were more often treated with mastectomy and less often with chemotherapy and/or radiation. BCSS was shorter in secondary BC patients than primary BC patients, but the survival difference between secondary and primary BC diminished with age [15-39 hazard ratio (HR): 2.09, 95% confidence interval (CI) 1.83-2.39; 40-64 HR: 1.51; 95% CI 1.44-1.58; ≥ 65 HR: 1.14; 95% CI 1.10-1.19]. Survival differences were most pronounced in women with hormone receptor positive disease and Hispanic and Asian/Pacific Islanders 40-64 years of age. CONCLUSIONS: When BC is diagnosed following a prior cancer of any organ site, BCSS is worse than when compared with patients for whom BC is the primary diagnosis, suggesting that we may need to tailor our treatments for women with secondary BC.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias Primarias Secundarias Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias Primarias Secundarias Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos